Analysis

'IV Cocktail' Ads Stir FTC To Prioritize Health Enforcement

Law360 (September 25, 2018, 9:14 PM EDT) -- The Federal Trade Commission last week required a company to stop marketing its intravenous therapy "cocktails" as a treatment for serious diseases without scientific proof, a first-of-its-kind action that signals the agency has made false claims concerning health and safety an enforcement priority.

The FTC’s suit last week accused A&O Enterprises Inc. and its owner Aaron K. Roberts of making deceptive claims about the company's IV Cocktails and their ability to treat ailments including cancer, multiple sclerosis and heart failure, in violation of the Federal Trade Commission Act. A settlement in the case prohibits the company from continuing to make those...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS